Regulatory Roundup: International Conference on Harmonization Hosts a Series of New Training Sessions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: International Conference on Harmonization Hosts a Series of New Training Sessions

ePT--the Electronic Newsletter of Pharmaceutical Technology

The International Conference on Harmonization (ICH) is hosting a series of new training sessions this spring. A follow-up training program to the organizations ICH Q8, Q9, and Q10 Quality Implementation program will take place in Japan. The workshop will provide comprehensive information on the integrated quality-trio guidelines and is cosponsored by the Japan Pharmaceutical Manufacturers Association and the Pharmaceutical and Medical Device Regulatory Science Society of Japan.

In related news, the ICH Global Cooperation Group (GCG) endorsed the SADC training for regulators on the ICH Q7 guideline (GMP for APIs). The training is scheduled for this summer in Tanzania. GCC also endorsed ASEAN's request for training regulators and industry on the ICH Q5C guideline (quality of biotechnological products) and that training will take place this spring Kuala Lumpur. Finally, GCC endorsed a request for training on the ICH Q5 series of guidelines (Q5A - Q5E) on quality of biotechnological products, which will take place in spring 2011. Visit the ICH website for further details on these programs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here